At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,548 enrolled
Drug / intervention
mRNA-1273.529 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 (Prototype) Booster Vaccine
In Brief
A Phase 3 clinical trial evaluating mRNA-1273.529, mRNA-1273, and 1 other intervention for SARS-CoV-2. Completed, enrolled 3,548 participants across 29 sites.
Detailed Summary
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartFeb 2022
First PostedFeb 2022
Primary CompletionJun 2023
TodayJul 2026
First PostedFeb 22, 2022
Enrollment StartFeb 16, 2022
Primary CompletionJun 23, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.4 years ago
Interventions
mRNA-1273.529biological
Sterile liquid for injection
mRNA-1273biological
Sterile liquid for injection
mRNA-1273.214biological
Sterile liquid for injection